RECORD 08 / CONTACT
Contact Meds Wolverine
Editorial correspondence about the BPC-157 TB-500 research record — corrections, sources, and questions about the literature.
Editorial correspondence only
Meds Wolverine is an independent BPC-157 TB-500 research digest, and this contact channel is for editorial matters only. We welcome corrections, source suggestions, and pointers to studies we have missed — particularly any controlled combination trial of BPC-157 with TB-500, which would change how we log the blend.
What this channel is not: it is not a route to obtain the blend or either constituent, not a request line for dosing or protocols, and not a clinical or prescribing service. We do not sell, supply, or source any peptide, and we cannot advise on personal use. Messages asking for product, price, or administration guidance will not receive that information.
What to expect
Use the form to reach the editorial desk. If you are flagging a factual error, a citation that should be corrected, or a regulatory update — for example a development in the FDA 503A review — please include the primary source so we can verify it against the record before changing any page. We read against sources, not against assertions.
For the regulatory picture as it currently stands, see the Wolverine legal status and 503A compounding record. For the science, the full reference list holds every study we cite.